How to Run a Cold Email Campaign for AI Leaders in Healthcare & Life Sciences (2026)

Quick answer: You can build a targeted list of AI leaders in healthcare and life sciences inside Origami, then craft and send a multi‑touch sequence directly from Origami’s built‑in email sequencer—no exporting, no separate tools. This guide walks through refining your list, stealing a 3‑touch email sequence that speaks to real healthcare AI buying triggers, and sending it all from a single dashboard.

You already used the companion post on how to build a list of AI leaders in healthcare & life sciences to generate a raw prospect list with Origami. Now I’ll show you exactly what to do after that—how to turn names and verified emails into replies and meetings. I’ve run variations of this campaign for companies selling AI infrastructure, MLOps platforms, and compliance tooling into pharma, biotech, and hospital systems. The numbers below are based on real sends in 2026.

---

1. Refine and qualify your list before you hit send

Your raw list from Origami already has names, verified work emails, job titles, company details, and sometimes tech‑stack signals. But not every contact is worth emailing. Go through the list and segment ruthlessly—otherwise you’ll burn leads and damage your sender reputation.

What “qualified” looks like for this audience

In healthcare and life sciences, AI leadership is a relatively new role. You want people who own a budget line for AI tools, not researchers who publish papers and have no purchasing authority. Filter for:

• Job titles that carry a P&L: Chief AI Officer, VP of AI / ML, Head of Data Science, Director of AI Engineering, Senior Director of Digital Health. Avoid pure academics (e.g., “Principal Scientist” without a commercial remit) unless they are a clear champion.
• Company size: For a complex sale, target organisations with >200 employees and a dedicated AI team. In pharma, that typically means mid‑market to enterprise (500–10,000 employees). Early‑stage biotechs often outsource AI, so their “AI leader” might just be a part‑time advisor—less likely to buy.
• Sub‑industry: Segment by vertical so you can tailor messaging. Pharma (drug discovery, clinical trials), biotech (genomics, protein folding), medical devices (image diagnostics), hospital networks (operational AI), and digital health startups all speak different languages.
• Geography: If you sell into regulated markets, prioritise US, EU, and UK where FDA/EMA compliance matters. For less regulated product lines, India and Singapore have booming AI‑healthcare hubs.

In Origami you can filter directly by title keywords, company size, industry tags, and location. If a lead doesn’t meet your criteria, simply remove them. The goal is a focused list of 50–200 truly qualified decision‑makers, not a spray‑and‑pray blast.

If you’re on the free plan (1,000 credits, no credit card), you can enrich and verify the first batch of leads to test the waters. Paid plans start at $29/month, and the email sequencer is included on every paid tier—you only pay for the credits you burn on enrichment, not for sending.

---

2. Create the email sequence (copy‑paste these three messages)

Inside Origami, you have two options to turn your list into a sequence:

1. Paste your own templates and set the delays between touches (e.g., Day 1, Day 3, Day 7). Then hit launch. I recommend this route if you’ve already A/B tested messaging and just need a delivery layer.
2. Let the AI agent write it – ask Origami to generate a personalised 3‑day sequence based on each lead’s profile (title, company, industry). The agent crafts custom intros, references relevant use cases, and adapts the call‑to‑action. It’s fast if you’re starting cold.

Below is the exact 3‑touch sequence I’ve used to get replies from AI leaders at top‑20 pharma and hospital groups. Feel free to paste these into Origami as your template. Every message is 50–100 words, no fluff, and speaks to the specific pressures healthcare AI execs face in 2026.

Day 1 – Initial cold email

Subject: AI governance at

Preview text: Quick question on your 2026 roadmap

Hi ,

I saw your recent work building out the AI team at . Are you responsible for how the team validates models before they touch patient data?

We help AI leaders in life sciences cut validation time from weeks to hours while keeping a full audit trail for FDA/EMA submissions. Think of it as a governance layer between experiment and production.

Worth a 15‑minute call to see if it fits your 2026 roadmap?

Best,

Day 3 – Follow‑up (different angle)

Subject: Re: AI governance at

Hi ,

I’m following up because the biggest pushback I hear from healthcare AI leaders is that their data science teams spend more time documenting model decisions than actually building models.

One mid‑sized pharma team we’re working with reduced their regulatory prep time by 60% after standardising their validation workflows. That time is now going into new indications.

Is reducing that “paperwork tax” on your roadmap at all?

Day 7 – Breakup email

Subject: Re: AI governance at

Hi ,

I’ll assume the timing isn’t right. If validation and governance become a bottleneck later this year, I’m happy to share how other healthcare AI teams are speeding up their regulatory submissions without adding headcount.

In the meantime, here’s a 2‑minute video showing the process: [link]

Good luck with the rest of Q1.

These messages work because they’re tethered to a concrete, urgent pain point for this audience: the tension between moving fast with AI and staying compliant. The CTA is always a conversation, never a demo. The breakup leaves the door open without begging.

If you prefer the AI‑written option, you can prompt Origami with something like:

“Write a 3‑touch cold email sequence for AI leaders in healthcare and life sciences. Focus on AI governance and regulatory documentation. Keep each email under 100 words, and use a conversational tone.”

The agent will generate variations for each lead, but I still recommend keeping a human eye on the first few sends.

---

3. Send the sequence directly from Origami

This is where Origami saves you the headache of juggling tools. The built‑in email sequencer lets you launch the campaign from the same dashboard where you built your list. No CSVs to export, no SMTP settings to fumble with—the enriched contacts live in one place.

Here’s the flow:

• Pick your list — the refined segment of AI healthcare leaders you qualified in Step 1.
• Assign the sequence — paste the three messages above (or the AI‑generated version) and set the delays: Day 1, Day 3, Day 7. You control the cadence.
• Launch — the sequencer starts sending automatically. Each lead gets the emails in order, and if they reply, they’re automatically un‑enrolled. No accidental breakup message after someone books a call.
• Track from one dashboard — opens, clicks, and replies appear alongside each contact’s enriched profile (title, company, tech used). So when you see a click, you still have the full context of why you reached out in the first place. No switching tabs.

The sequencer is included on all paid plans — you’re only paying for the credits to enrich leads, the sending itself is free. If you’re testing, start with 50–100 leads on a low‑cost plan, see what works, then scale.

What response rate to expect

With a well‑qualified list and the sequence above, I typically see a reply rate of 7–12% for healthcare AI executives in 2026. That’s not an open rate; these are actual replies, often asking for a call or more information. If your list is narrower (e.g., only FDA‑regulated AI shops) and your messaging is extremely relevant, you might push 15%. If it’s below 4%, check two things: your list quality (are you reaching real decision‑makers?) or your message (is it too generic?).

A common mistake: emailing a list of data scientists instead of AI leaders. Data scientists often have no budget; AI leaders do. If reply rates are low, re‑run the list in Origami with stricter title criteria before you rewrite the whole sequence.

When to iterate on messaging vs. iterate on the list

• Iterate on messaging if you see high opens (above 55%) but low replies. That means your subject line and preview text are working, but the body isn’t compelling enough. Test a different pain point (data privacy, model drift, ROI proof) in the Day 1 message.
• Iterate on the list if open rates are low (below 40%). That usually means the emails are landing in spam, the contacts are inaccurate, or you’re not hitting real work addresses. Use Origami’s enrichment to double‑verify emails and add missing data before you change the copy.

---